ReviewCancers2022

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced

Jianchao Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.